Reality Check? Medicaid Costs From Cell, Gene Therapies Projected At (Just) $1Bn-$4Bn By 2030

Based on the current pipeline of durable therapies, MIT research indicates ‘it’s not a big lift to cover the children and the adults in Medicaid for these products,’ Mark Trusheim says.